Elanco Animal Health Incorporated (NYSE:ELAN) is one of the stocks Jim Cramer shed light on. Answering a caller’s query about the stock, Cramer said: “They are doing everything right. I am so impressed with the way they’ve turned that company around. I’m glad you brought it out. That was a real good idea.” A laptop and a computer monitor display a detailed stock market technical analysis chart. Photo by Jakub Zerdzicki on Pexels Elanco Animal Health Incorporated (NYSE:ELAN) sells products to protect a ...

Agriculture Biotechnology Market by Type of Organism (Plant, Animal, and Microbes), Type, Technology, Application, and Region - Global Forecast to 2030 The global agriculture biotechnology market was valued at USD 84.39 billion in 2024 and is projected to reach USD 144.25 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.4% during 2025–2030. Market growth is fueled by the rising adoption of genetically modified (GM) crops, microbial biofertilizers, animal vaccines, and sustainable biote ...

iiiii Credelio Quattro-CA1 now joins Credelio (lotilaner) and Credelio CAT (lotilaner) on the list of companion animal treatment options for New World screwworm, with these other products recently receiving FDA Emergency Use Authorization for the treatment of New World screwworm infestations in dogs and cats, respectively. According to USDA, there have been 14 cases of New World screwworm within 400 miles of the U.S.-Mexico border, all of them related to cattle movement. With detection reaching as close as ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Elanco Animal Health Incorporated (NYSE:ELAN) . “They are doing everything right. I am so impressed with the way they've turned that company around,” he added.Lending support to his choice, Barclays analyst Glen Santangelo, on Dec. 9, initiated coverage on Elanco Animal Health with an Overweight rating and announced a price target of $30.Rocket Lab Corporation (NASDAQ:RKLB) is a “very good spec, ahead of another big offering in the rocket ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Elanco Animal Health Incorporated (ELAN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.Elanco Animal Health Incorporated is a member of the Medical sec ...

Investors might want to bet on Elanco Animal Health Incorporated (ELAN) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate ...

Core Insights - Elanco held its 2025 Investor Day, discussing forward-looking statements and financial expectations [1] - The company emphasized that its remarks would focus on non-GAAP financial measures, excluding the Aqua business divested on July 9, 2024 [2] Financial Performance - The discussion included organic performance metrics, which do not account for the impact of the Aqua business [2]

Core Viewpoint - Elanco Animal Health is entering a new phase focused on sustainable growth, margin expansion, and a stronger balance sheet, as outlined during its first Investor Day in five years [1] Financial Outlook - Elanco projects mid-single-digit organic revenue growth, high-single-digit adjusted EBITDA growth, and low-double-digit adjusted EPS growth starting in 2026 [2] - The company anticipates free cash flow of at least $1 billion from 2026 to 2028, with net leverage expected to fall below 3x in 2027, targeting a long-term range of 2.0x to 2.5x [2] R&D Investments - Elanco plans to expand R&D operations in Indianapolis and increase its U.S.-based manufacturing footprint, including investments in its Kansas monoclonal antibody facility [3] - The company expects approximately $1.1 billion in revenue from its innovation portfolio in 2026, an increase from prior expectations for 2025 [4] - Elanco has expanded its focus to eight innovation areas and added two new internal development platforms in monoclonal antibodies and immunotherapy [4] - More than 10 major pipeline programs are in place, with approvals expected for five to six differentiated assets between 2026 and 2031 [5] Cost Initiatives - Elanco detailed its Ascend productivity initiative, expecting $25 million in savings in 2026 and $60 million in 2027, affecting 600 roles through reductions or shifts [6] - A related charge of approximately $175 million is anticipated, with the Ascend program expected to deliver $200 to $250 million in adjusted EBITDA savings by 2030, achieving about 30% of this in 2026 [6] Analyst Insights - Analysts noted initial details on over 15 projects in key areas, including five to six blockbusters, positioning Elanco for three waves of innovation over the next decade [9] - If Elanco successfully executes its pipeline, it is expected to deliver upside to its long-term financial targets [9] - Elanco shares were trading at 21 times the 2026 EPS estimate, with an Outperform rating maintained by analysts [10]

Core Viewpoint - Elanco Animal Health is entering a new phase focused on sustainable growth, margin expansion, and a stronger balance sheet, as outlined during its first Investor Day in five years [1] Financial Outlook - Elanco projects mid-single-digit organic revenue growth, high-single-digit adjusted EBITDA growth, and low-double-digit adjusted EPS growth starting in 2026 [2] - The company anticipates free cash flow of at least $1 billion from 2026 to 2028, with net leverage expected to fall below 3x in 2027, targeting a long-term range of 2.0x to 2.5x [2] R&D Investments - Elanco plans to expand R&D operations in Indianapolis and increase its U.S.-based manufacturing footprint, including investments in its Kansas monoclonal antibody facility [3] - The company is progressing towards final USDA approval for Befrena, a potential blockbuster dermatitis treatment for dogs, with a launch expected in the first half of 2026 [4] - Elanco forecasts approximately $1.1 billion in revenue from its innovation portfolio in 2026, an increase from prior expectations for 2025 [4] - The company has expanded its focus to eight innovation areas and added two new internal development platforms in monoclonal antibodies and immunotherapy [4] - More than 10 major pipeline programs are expected to carry blockbuster potential, with approvals anticipated for five to six differentiated assets between 2026 and 2031 [5] Cost Initiatives - Elanco detailed its Ascend productivity initiative, expecting $25 million in savings in 2026 and $60 million in 2027, affecting 600 roles through reductions or shifts [6] - A related charge of approximately $175 million is anticipated, with the Ascend program expected to deliver $200 to $250 million in adjusted EBITDA savings by 2030, with about 30% achieved in 2026 [6] - The initiative positions Elanco for durable, profitable growth with continued margin expansion and strong cash generation into the latter half of the decade [7] Analyst Insights - Analysts noted initial details on over 15 projects in key areas, including five to six blockbusters, positioning Elanco for three waves of innovation over the next decade [9] - If Elanco successfully executes its pipeline, it is expected to deliver upside to its long-term financial targets [9] - Elanco shares were trading at 21 times the 2026 EPS estimate, with an Outperform rating maintained by analysts [10]

Core Insights - The article discusses the importance of enabling Javascript and cookies in browsers to ensure proper functionality and access to content [1] Group 1 - The article emphasizes that users may face access issues if ad-blockers are enabled, suggesting the need to disable them for a better experience [1]